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Abstract
Background: Peritonitis is the main cause of withdrawal from peritoneal dialysis (PD) therapy in Japan. The precise
extent of PD-associated peritonitis in Japan has not been investigated since 2005; we aimed to clarify the recent
incidence and prognosis of PD peritonitis.
Methods: The 248 institutional members of the Japanese Society for Peritoneal Dialysis were surveyed by questionnaire
regarding peritonitis episodes during January 1 to December 31, 2013.
Results: Replies from 114 members were received regarding 3042 PD patients, including 516 peritonitis patients,
covering a total observation period of 31,686 patient months. The incidence of peritonitis in this study was 0.195
episodes per year. Detailed data on 544 peritonitis episodes in 466 patients was obtained. The causes, in ranked
order, were unknown reason, contamination at peritoneal fluid exchange, and extension of intra-abdominal
cavity infection. Effluent culture methods included using a blood culture bottle (50.9 %), large-volume culture
(culturing sediment after centrifuging effluent) (31.7 %), and direct culture of effluent using a culture dish
(12.7 %). The rank order of microbes identified in peritoneal effluent cultures was culture-negative, Streptococcus sp.
and Staphylococcus aureus. Empiric therapy with two kinds of antibiotics was administered to 406 cases (75.2 %), most
commonly cefazolin + ceftazidime. Antibiotic administration methods included intraperitoneal (51.4 %), intravenous
(46.4 %), and oral (2.2 %). After a peritonitis episode, 461 patients (84.7 %) continued PD therapy, 80 (14.7 %) withdrew
from PD treatment, and 6 (1.1 %) died. Prognosis among patients grouped by antibiotic administration method
was statistically significantly different; in the oral administration group, the rates of mortality and catheter
replacement were higher. Logistic regression analysis showed that catheter exit-site infection and frequency
of past peritonitis episodes were independent factors associated with PD treatment withdrawal.
Conclusions: Although the overall incidence of PD peritonitis in Japan was relatively low, several areas for future
improvement were identified: unknown reason and culture-negative were the most frequently cited causes of
peritonitis; 1.1 % of patients died, and 13.6 % discontinued PD therapy. Improvements in effluent culture techniques,
antibiotic administration methods, etiology determination, and patient education could help. A more effective protocol
must be established to further improve the treatment of PD peritonitis in Japan.
Keywords: PD peritonitis incidence, Effluent culture technique, Antibiotic administration methods, Catheter exit-site
infection, Previous peritonitis episodes
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Background
Peritonitis is the major cause of discontinuation of peri-
toneal dialysis (PD) therapy, reportedly accounting for
34 % of such cases in Japan [1]. There is a recent report
regarding PD peritonitis in Japan, but that study was not
conducted nationwide [1]. The precise extent of PD-
associated peritonitis in Japan has not been investigated
since 2005 [2]. Annual nationwide statistical analysis of
Japanese PD patients was begun in 2010 by the Japanese
Society of Dialysis Therapy (JSDT), but only the periton-
itis incidence rate was ascertained in those investigations
[3, 4]. Therefore, we aimed to clarify the recent incidence
and prognosis of PD peritonitis using a nationwide ques-
tionnaire survey.
Methods
We conducted a questionnaire survey of the 248 insti-
tutional members of the Japanese Society for Peritoneal
Dialysis (JSPD) regarding PD-associated peritonitis epi-
sodes occurring for 1 year (January 1 to December 31,
2013). Replies from 114 institutions were received. The
questionnaire sought information about each peritonitis
patient as follows: clinical characteristics, frequency of
past peritonitis episodes, PD fluid bag exchange system,
cause of peritonitis, effluent microbiology and method of
culture, type of antibiotics administered and administra-
tion methods, peritonitis treatment period, and prognosis
(Additional file 1).
All study participants provided informed consent, and
the study design was approved by the Institutional Com-
mittee on Human Research of Tokyo Women’s Medical
University and Yabuki Hospital.
Statistical analysis
We analyzed the influence of the antibiotic administra-
tion method on prognosis using Pearson’s chi-square
test. We also analyzed the association between various
clinical findings and the interruption of PD (including
mortality) using logistic regression analysis. Continuous
variables are expressed as mean ± standard deviation.
Differences having P values <0.05 were considered statis-
tically significant.
Results
Incidence of peritonitis
From 114 institutions (26 university hospitals, 67 hospitals
with more than 100 beds, 4 clinics with beds for admission,
17 clinics without beds for admission), information regard-
ing 3042 PD patients, including 516 peritonitis patients,
was obtained, covering a total observation period of 31,686
patient months. The incidence of peritonitis was calculated
to be 0.195 episodes per year.
Peritonitis patient characteristics
We obtained the clinical characteristics of the 466 peri-
tonitis patients who had a total of 544 peritonitis epi-
sodes; 59 patients had multiple peritonitis episodes (an
episode that occurred within 2 weeks of completion of
therapy for a prior episode was defined as 1 peritonitis
episode). Characteristics of these 466 patients are shown
in Table 1. The average frequency of past peritonitis epi-
sodes was 0.85 ± 1.20. There are two methods used in
Japan for connecting a PD fluid bag to the catheter. One
is by manual connection, and the other involves use of
machinery for ultraviolet irradiation or heat sealing of
the catheter to the PD fluid bag. The numbers of epi-
sodes using each were manual method, 206 and ma-
chinery device method, 303. There was no statistical
difference between manual connection and machinery
device connection methods for the frequency of past
peritonitis episodes.
Characteristics of 544 peritonitis episodes are shown
in Table 2. The average PD treatment duration at the
time of a peritonitis episode was 36.1 ± 32.7 months; 407
patients had 1 episode of peritonitis, and 59 patients had
several peritonitis episodes during the study period.
Table 1 Characteristics of 466 PD peritonitis patients
Clinical characteristics
M/F/not described 296/167/3
Age (y/o) 65.2 ± 14.0 (range, 4–96)
Original disease
Diabetes mellitus 159 (34.1 %)
Chronic glomerulonephritis 131 (28.1 %)
Nephrosclerosis 62 (13.3 %)
Polycystic kidney disease 18 (3.9 %)
Others 89 (19.1 %)
Unknown 7 (1.5 %)
Automated PD 140 cases
Combined therapy with HD 71 cases
Frequency of past peritonitis 0.85 ± 1.20
None 236 patients
1 time 139
2 times 44
3 times 22
4 times 13
5 times 2
6 times 5
7 times 1
Unknown 4
Connection method
Manual/machinery device/unknown 206/303/35
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Causes of peritonitis
The causes cited for peritonitis episodes included the
following: contamination during the peritoneal fluid bag
exchange (touch contamination), 130 episodes (23.9 %);
influence of intra-abdominal cavity infection, 58 episodes
(10.7 %); exit-site infection, 55 episodes (10.1 %); and
unknown, 207 episodes (38.1 %) (Fig. 1).
Bacterial cultures of peritoneal effluent
Figure 2 depicts the various methods of effluent culture
reported in this survey, including the use of a blood cul-
ture bottle, 50.9 %; large-volume culture (culturing the
effluent sediment after centrifugation, in a culture dish
or blood culture bottle), 31.7 %; and direct culture of ef-
fluent in a culture dish, 12.7 %.
Microbiology of effluent cultures
Among effluent cultures, 131 episodes were culture-
negative, 270 episodes yielded Gram-positives, 116 yielded
Gram-negatives, and 42 yielded “other” microbes (Table 3).
In addition, 32 episodes were poly-microbial. The rank
order of infecting organisms was culture-negative bacteria,
Streptococcus sp. and Staphylococcus aureus.
Antibiotic treatments
Initially, empiric antibiotic treatments were reported
for 540 episodes (Fig. 3). Cefazolin (CEZ) was the most
frequently selected agent, followed by ceftazidime
(CAZ), vancomycin (VCM), cefotiam (CTM), and cef-
metazole (CMZ). In total, 406 episodes (75.2 %) were
treated with antibiotic combinations: the second anti-
biotic agents used in combination therapy included
CAZ, tobramycin (TOB), VCM, CEZ, and amikacin
(AMK). Only one case was treated empirically with
three antibiotics. The most common combination ther-
apy was CEZ + CAZ (112 cases).
Administration methods for first antibiotic agents in-
cluded intraperitoneal (IP), 277 (51.4 %) cases and
intravascular (IV), 250 (46.4 %) cases. Administration
methods for second antibiotic agents were IP, 236
(59.4 %) cases and IV, 145 (36.5 %) cases. Mean treat-
ment periods were 8.9 ± 5.6 days for first antibiotics
and 8.0 ± 5.2 days for second antibiotics. The mean
treatment period for cases receiving only empiric ther-
apy was 10.8 ± 5.4 days.
After the first, empiric antibiotic administration, 278
cases were switched to targeted antibiotics; 79 of these
were treated with two antibiotics and 5 were treated
with three antibiotics. The mean total length of therapy
with targeted antibiotics was 16.5 ± 9.3 days.
Table 2 Characteristics of 544 peritonitis episodes of 466 PD
patients
Clinical characteristics
PD treatment duration at the time of peritonitis (months) 36.1 ± 32.7
Frequency of peritonitis during the study (cases)
1 time 407
2 times 43
3 times 13
4 times 3
Recurrent peritonitis 19
Relapsing peritonitis 11
Repeat peritonitis 14
Recurrent peritonitis an episode that occurs within 4 weeks of completion of
therapy for a prior episode but with a different organism, Relapsing peritonitis
an episode that occurs within 4 weeks of completion of therapy for a prior
episode with the same organism or a sterile episode, Repeat peritonitis an
episode that occurs more than 4 weeks after completion of therapy for a prior
episode with the same organism
Catheter operation       10   
(1.8%)
Unknown                       207
(38.1%)       
Touch contamination     130 
(23.9%)
Infection of intra        58
-abdominal cavity     (10.7%)
Exit-site tunnel infection   55         
(10.1%)
Others                    32 
(5.9%)
No record              29
(5.3%)
Defective device      23
(4.2%)
Fig. 1 Causes of peritonitis
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Effect of treatment
Of the 544 peritonitis episodes, 461 (84.7 %) were able to
continue PD treatments after the peritonitis resolved: 19
(3.5 %) underwent removal and reinsertion of the catheter.
However, 80 (14.7 %) withdrew from PD treatment and
transferred to periodic hemodialysis treatment, and 6
(1.1 %) died. The prognosis of three patients was not ob-
tained from the questionnaires.
The main microorganisms of cases withdrawn from
treatment were as follows: methicillin-resistant S. aur-
eus (MRSA), 12; S. aureus, 6; Escherichia coli, 6; other
Gram-negative, 6; other bacteria, 6; Streptococcus sp., 5;
Pseudomonas sp., 5; and culture-negative, 15. The total
treatment period for peritonitis in these cases was 20.5
± 13.7 (1~80) days.
Bacteria causative of the six deaths were as follows:
MRSA, two; Escherichia coli (E. coli), one; Pseudomonas
sp., one; other bacteria, one; and culture-negative, one.
The course of one patient who died was complicated by
hepatic carcinoma and relapsing peritonitis, and the
infection routes in the other five patients were touch
contamination, three; extension of intra-abdominal cav-
ity infection, one; and unknown reason, one. Antibiotic
administration methods were IP, one; IV, four; and oral,
one. The mean treatment period for these six patients
was 10.3 ± 5.5 days (range 1–17 days).
Antibiotic administration method and prognosis
We analyzed the influence of empiric antibiotic adminis-
tration method on prognosis using Pearson’s chi-square
test (Fig. 4). In the oral administration group, the rates
of mortality and catheter replacement were higher than
those in the IV or IP groups. The rates of PD continu-
ation, catheter replacement, withdrawal from PD, and
mortality among groups of patients undergoing the three
different antibiotic administration methods (oral, IV, and
IP) were statistically different (P < 0.0001).
Clinical findings and PD treatment withdrawal
We examined the association of clinical findings and
PD treatment withdrawal using logistic regression ana-
lysis. The dependent variable was withdrawal from PD
337 (50.9%)210 (31.7%)
84 (12.7%)
31 (4.7%)
Culture bottle
Large-volume culture
(culturing the sediment
after centrifuging effluent)
Direct culture in culture dish
Other
Fig. 2 Effluent culture methods (including overlapping answers)
Table 3 Microbiology of peritoneal effluent cultures (including
overlap)
Gram-positives 270
Staphylococcus aureus 52
Staphylococcus epidermidis 30
Methicillin-resistant Staphylococcus aureus 34
Other Staphylococcus sp. 23
Streptococcus sp. 75
Corynebacterium sp. 19
Enterococcus sp. 19
Other 18
Gram-negatives 116
Pseudomonas sp. 21
Serratia sp. 9
Alcaligenes sp. 0
Escherichia coli 25
Neisseria sp. 1
Stenotrophomonas maltophilia 3
Acinetobacter sp. 16
Klebsiella sp. 19
Citrobacter sp. 3
Other 19
Other 42
Candida sp. 6
Aspergillus 1
Other organism 35
Culture-negative 131
Higuchi et al. Renal Replacement Therapy  (2016) 2:2 Page 4 of 8
(including death); the independent variables were age,
PD treatment period, original disease, exit-site infection,
touch contamination, intra-abdominal cavity infection, in-
fection from defective device and methodology, infection
at catheter placement, and frequency of past peritonitis.
We selected the statistically significant variables from
these independent variables using the stepwise method;
PD treatment period, exit-site infection, intra-abdominal
cavity infection, and frequency of past peritonitis were
then analyzed using logistic regression analysis. A signifi-
cant association was observed between withdrawal from
PD treatment and exit-site infection (OR 2.56, P = 0.007)
as well as between withdrawal from PD and frequency of
past peritonitis (OR 3.041, P < 0.0001) (Table 4). Based on
these results, exit-site infection and frequency of past peri-
tonitis were considered important factors that affect the
prognosis of PD peritonitis patients.
Discussion
In this study, we examined the characteristics of PD
peritonitis patients in Japan in 2013 using a question-
naire survey. According to previous reports published by
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Treatment periods
8.0± 5.2 days
b
0 20 40 60
CAZ
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CEZ
VCM
IP
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Treatment periods
9.6± 6.4 days
c
(Cases)
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CCL
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d
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Fig. 3 Antibiotic therapy: administration methods and durations. a First empiric antibiotic (540 cases). b Second empiric antibiotic (406 cases).
c Third antibiotic, targeted for known susceptibility (278 cases). d Fourth antibiotic, targeted for known susceptibility (79 cases). In total, 406 cases
(75.2 %) were treated with combined empiric therapy; 278 cases were switched to targeted antibiotics after empiric antibiotic administration.
Intraperitoneal administration: 277 (51.4 %) for first antibiotic and 236 (59.4 %) for second antibiotic. Total administration periods were 16.5 ±
9.3 days. CEZ cefazolin, CAZ ceftazidime, VCM vancomycin, CTM cefotiam, CMZ cefmetazole, TOB tobramycin, AMK amikacin, MEMP meropenem,
LVFX levofloxacin, CCL cefaclor, RFP rifampicin, IP intraperitoneal cavity administration, IV intravenous administration
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JSDT [3, 4], 9245 and 9510 patients were treated with
PD therapy in 2013 and 2012, respectively, in Japan. In
these statistical surveys, incidences of peritonitis in 2013
and 2012 were 0.22 and 0.21 episodes per year among
4197 and 4180 PD patients, respectively, compared to
the current finding of 0.195 episodes per year among
3042 patients.
The reported incidences of peritonitis were 0.60, 0.95,
and 0.29 episodes per year in Australia and New Zealand
[5], the Netherlands [6], and Brazil [7], respectively. From
these reports, the incidence of peritonitis in Japan can be
considered a relatively good result. We think that one of
the reasons for the low incidence of peritonitis is that in
Japan, many patients use a machinery device to connect
the dialysis fluid bag and the catheter. However, there was
no statistical difference between manual and machinery
device connection methods regarding the frequency of
past peritonitis episodes. Since 2004, all glucose PD solu-
tions have been changed to neutral-pH and low glucose
degradation product (GDP) solutions in Japan. As there
have been several reports that the peritonitis rate was
lower in patients using neutral-pH and low GDP solutions
[8, 9], we considered whether this might be another rea-
son for the low rate. However, a randomized study [10]
demonstrated that the peritonitis rate was not statistically
different between groups using the biocompatible PD
solution or the conventional solution. This issue needs
further analysis in future studies.
In this study, the main causes of peritonitis were “un-
known cause,” “touch contamination”, and exit-site infec-
tions. Furthermore, about 50 % of patients experienced
peritonitis one or more times before the study period.
Physicians should evaluate in more detail the peritonitis
etiology in each patient in an effort to prevent repeat and
recurrent peritonitis.
In this study, and in previous national [2] and recent
global [5, 6] studies, Gram-positive organisms were the
most common pathogen. Coagulase-negative staphylo-
cocci and S. aureus were the most common organisms
in many reports, but Streptococcus sp. were the most
common in this study and in reports from Taiwan [11]
and Spain [12].
In this study, 23.4 % of peritonitis cases were culture-
negative. The International Society for Peritoneal Dialysis
(ISPD) guideline recommendations [13] have stated that
the culture-negative peritonitis rate should not be greater
than 20 % of episodes and that the large-volume culture
method (culturing the sediment after centrifuging the ef-
fluent) is recommended. However, only 31.7 % cases re-
ported here included use of this method. We should
encourage use of this culture method by educating the
staff of PD hospitals.
Regarding empiric antibiotic treatment, CEZ was the
most frequently selected therapy; 75.2 % cases were treated
with combined antibiotics, and the most frequent second
antibiotic was CAZ. ISPD guidelines/recommendations
0%
20%
40%
60%
80%
100%
Oral IP IV
  Mortality
  Withdrawal from  PD
  Catheter replacement
  PD continuation
Fig. 4 Influence on prognosis of empiric antibiotic administration method. The rates of PD continuation, catheter replacement, interruption of
PD, and mortality for the three different administration methods were statistically different (P < 0.0001). PD peritoneal dialysis, IP intraperitoneal
cavity administration, IV intravenous administration
Table 4 Association between interruption of PD and clinical
findings
Catheter removed Odds
ratio
95 % CI
interval
P value
PD treatment periods 1.005 0.997–1.012 0.1848
Exit-site tunnel infection 2.560 1.292–5.071 0.007
Infection of intra-abdominal
cavity
1.585 0.769–3.269 0.212
Frequency of past peritonitis 3.041 1.787–5.1741 <0.0001
The association of several clinical findings and PD treatment withdrawal using
logistic regression analysis. Four clinical findings were selected as statistically
significant variables using the stepwise method, and exit-site tunnel infection
and frequency of past peritonitis were significantly associated with withdrawal
from PD treatment by logistic regression analysis
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[14] include use of combination antibiotics, such as vanco-
mycin or cephalosporin along with third-generation cepha-
losporins, including CAZ, or aminoglycosides, to cover
Gram-positive and Gram-negative organisms, respectively.
This recommendation was introduced based on the effi-
cacy results of a randomized controlled study of use of the
combination CEZ and CAZ for empirical treatment [15].
Prolonged therapy with vancomycin may predispose to in-
fections with vancomycin-resistant S. aureus (VRSA) or
vancomycin-resistant enterococci (VRE). In this study,
vancomycin was the third choice for empiric therapy. In
Japan, there are no data regarding development of VRSA
or VRE infection during use of vancomycin therapy in PD
peritonitis patients. These issues need to be investigated in
future studies. Treatment length with empiric therapy was
8.9 ± 5.6 days, and the next antibiotic regimen was admin-
istered for 16.5 ± 9.3 days in this study. ISPD guidelines/
recommendations suggest that the minimum treatment
period should be 2 weeks, and 3 weeks is recommended
for more severe infections. In this study, 48.5 % were
treated by only empiric therapy for 10.8 ± 5.4 days. We
thought the treatment period in our country was shorter
than the recommended period. However, the length of
therapy in the ISPD guideline is based on opinions, and we
need further research to firmly establish the optimal treat-
ment period.
After a peritonitis episode, 84.7 % were able to continue
PD treatment, 14.7 % withdrew from PD treatment, and
1.1 % (six patients) died. The obvious causative pathogens
for these six were MRSA, E. coli, and Pseudomonas sp.,
and the treatment periods were 10.3 ± 5.5 days. Refractory
peritonitis should be managed by catheter removal when
treatment fails after 5 days of appropriate antibiotics
[13]. MRSA and Pseudomonas sp. are known, common
causes of refractory peritonitis, and we suggest that in
these six cases, the catheter should have been removed
at an earlier time.
The recommendations state that the preferred ad-
ministration method of antibiotics is IP compared to IV
or oral dosing, since IP dosing results in very high local
levels of antibiotics. However, 46.2 and 2.2 % of cases
in this study were dosed by IV and oral routes, respect-
ively, for empiric therapy. Among the six patients who
died, routes were IP, one; IV, four; and oral, one. We
analyzed the influence of the empiric antibiotic admin-
istration method on prognosis and found that the rates
of PD continuation, catheter replacement, withdrawal
from PD, and mortality in the three groups were statis-
tically different. We should emphasize the importance
of IP antibiotic administration for PD peritonitis. We
analyzed the influence of clinical findings on prognosis
and found that exit-site infection and frequency of past
peritonitis episodes were important factors. Ultrasonog-
raphy can facilitate the diagnosis of exit-site infections
[16]. For prevention of peritonitis from these infections,
management issues, such as use of ultrasonography, anti-
biotic administration timing and duration, and timing of
catheter replacement, should be considered. Recurrent
peritonitis has a lower primary response rate to antibi-
otics, a lower complete cure rate, and a higher mortality
rate compared with first peritonitis episodes and relapse
peritonitis [17]. It was reported that the total training time
and the timing of training for performance of PD are asso-
ciated with the peritonitis incidence rate [7]. We need to
consider methods to lower the incidence of recurrent and
repeat peritonitis, including better analysis of etiology and
improved individual patient retraining.
Limitations
This study analyzed data from approximately one third
of all Japanese PD patients. We could not obtain the
demographics for all 3042 PD patients, and we could
not make comparisons with data from non-peritonitis
patients. Another weakness of this study was the retro-
spective nature of data collection. More large-scale and
prospective studies that include non-peritonitis patients
are needed to clarify the current status of Japanese PD
peritonitis.
Conclusions
We summarized the state of peritonitis in the setting of PD
in 2013 in Japan. The incidence of peritonitis was 0.195 ep-
isodes per year; 84.7 % continued PD therapy after periton-
itis, and 1.1 % died. We identified some targets for
improvement in Japan. There were high rates of peritonitis
of unknown cause and culture-negativity and low rates of
use of the large-volume culture method and IP administra-
tion of antibiotics. Exit-site infection and frequency of past
peritonitis were independent risk factors for withdrawal
from PD treatment. These results indicate that we need to
improve etiology determination through the use of better
effluent culture techniques and more rigorous pathogen
identification, increased use of the optimal antibiotic ad-
ministration method, and improved patient education.
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